论文部分内容阅读
目的:研究细胞外信号调节激酶ERK(extracellular signal-regulated kinase,ERK)与卵巢癌临床病理特征、化疗反应以及生存预后之间的关系。方法:收集卵巢癌患者的临床资料,制备组织芯片,应用免疫组化法(Envision)测定正常卵巢/输卵管组织、交界性卵巢肿瘤组织和卵巢上皮性癌组织中,p-ERK(ERK磷酸化形式)表达情况,应用Kaplan-Meier法进行生存分析,用χ2检验检测p-ERK在卵巢癌组织中的表达情况。结果:58例有完整随访信息的卵巢癌患者生存分析结果示,p-ERK有表达的卵巢癌患者生存时间短,无表达者生存时间长。p-ERK表达与临床病理之间的关系分析结果示,p-ERK在卵巢癌组织中的表达高于交界性卵巢肿瘤组织和正常卵巢组织(P<0.05)。p-ERK在不同卵巢癌组织学类型中的表达差异无统计学意义(P>0.05)。p-ERK蛋白在Ⅲ-Ⅳ期卵巢上皮癌组织中的表达高于Ⅰ-Ⅱ期(P<0.05)。术前CA125值和p-ERK表达呈正相关,p-ERK有表达的患者术前CA125值高(P<0.05)。p-ERK有表达化疗有反应的患者生存时间长,化疗无反应的患者生存时间短(P<0.05)。结论:p-ERK蛋白在卵巢癌中的表达,是影响卵巢癌患者生存预后及化疗反应的一个重要因素。
OBJECTIVE: To study the relationship between extracellular signal-regulated kinase (ERK) and clinicopathological characteristics, chemotherapy response and survival and prognosis in ovarian cancer. Methods: The clinical data of patients with ovarian cancer were collected to prepare tissue microarray. Envision was used to detect the expression of p-ERK (ERK phosphorylation) in normal ovarian / oviduct tissue, borderline ovarian tumor and ovarian epithelial carcinoma ). Kaplan-Meier method was used for survival analysis. The expression of p-ERK in ovarian cancer tissues was detected byχ2 test. Results: Survival analysis of 58 patients with complete follow-up information of ovarian cancer patients showed that the survival time of patients with ovarian cancer with p-ERK expression was short, and those without expression had longer survival time. The analysis of the relationship between p-ERK expression and clinical pathology showed that the expression of p-ERK in ovarian cancer tissues was higher than that in borderline ovarian tumor tissues and normal ovarian tissues (P <0.05). The expression of p-ERK in different histological types of ovarian cancer had no statistical significance (P> 0.05). The expression of p-ERK protein in stage Ⅲ-Ⅳ epithelial ovarian cancer was higher than that in stage Ⅰ-Ⅱ (P <0.05). Preoperative CA125 values and p-ERK expression was positively correlated, p-ERK expression in patients with preoperative CA125 value (P lt; 0.05). Patients with p-ERK who responded to chemotherapy had longer survival time and patients who did not respond to chemotherapy had shorter survival (P <0.05). Conclusion: The expression of p-ERK protein in ovarian cancer is an important factor affecting the survival prognosis and chemotherapy response in patients with ovarian cancer.